Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis
about
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsPonatinib reduces viability, migration, and functionality of human endothelial cells.Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective studyThe prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosisThe adverse effects of sorafenib in patients with advanced cancers.Renal effects of targeted anticancer therapies.Onco-nephrology: current concepts and future perspectives.Renal Toxicities of Targeted Therapies.Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.Feasibility of 4D perfusion CT imaging for the assessment of liver treatment response following SBRT and sorafenibDeteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.Meta-analysis of randomized phase II trials to inform subsequent phase III decisions.Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.Bilateral above knee amputations after prolonged exposure to sorafenib and trebananib.Comprehensive review of cardiovascular toxicity of drugs and related agents.Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].Hypertension in malignancy-an underappreciated problem.
P2860
Q26765210-40A78169-689A-4349-A7DE-93366D5A98E4Q28066747-6CF42F39-0BD7-4075-B0D0-5F46C0AC7591Q28080163-F88BC094-6206-4B5C-B34A-9B3871EC34B7Q33364077-FE5C9D87-3AA1-4493-83CC-21F9135B597EQ36546814-F7A51AE2-290D-443B-B0AB-C8DEF809E326Q37131689-0D51E80B-BB49-46A2-AA40-E73BD8358B9DQ38286308-955FD09E-D037-4DC3-AA00-D533F5F7F927Q38367168-7977FC32-EB0B-4076-BD7A-0965F1B34A79Q38382457-4BEF804D-88DD-40AD-B37B-68BE8E878BC1Q38448007-50C1FBA8-D520-41D0-AF3E-AA47CDFF8887Q38473672-BD4D423D-B1DA-4C17-8EEE-A952E1059E0BQ38863883-9FA29F4D-4FB0-4D58-A710-23A83853E585Q38975450-70582BD7-0E07-45A4-85AB-16D81B312E72Q41038300-0B25BF8D-F904-4D9A-86EC-8E4B93D60056Q41853963-233B0D51-96BC-47DE-90E7-E229B3B2A92DQ42074538-351B45C5-1BDD-420A-82CB-FB013F18286EQ42359608-B5C05700-E25A-483D-A421-CB9B93901865Q42995965-ABE7047E-66EF-40AC-B672-033F94C0FA25Q47556269-4BDED8F5-E6F2-4338-9CE2-99F0364DCB95Q49134863-C8F6BCE4-0FF0-47FB-BB93-D0D0DC053D3FQ50512896-21DEE0DE-A405-4E9E-8D8C-245769281C3CQ50526652-E7468F19-37F5-4D2D-BF42-C2067E20E1BEQ54195816-7809379A-3DC7-40A8-9B6B-9C915C5E0A9BQ55071881-9E1B81E8-2199-4725-A538-1DEA772A4306
P2860
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Incidence and risk of sorafeni ...... matic review and meta-analysis
@ast
Incidence and risk of sorafeni ...... matic review and meta-analysis
@en
Incidence and risk of sorafeni ...... matic review and meta-analysis
@nl
type
label
Incidence and risk of sorafeni ...... matic review and meta-analysis
@ast
Incidence and risk of sorafeni ...... matic review and meta-analysis
@en
Incidence and risk of sorafeni ...... matic review and meta-analysis
@nl
prefLabel
Incidence and risk of sorafeni ...... matic review and meta-analysis
@ast
Incidence and risk of sorafeni ...... matic review and meta-analysis
@en
Incidence and risk of sorafeni ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P356
P1476
Incidence and risk of sorafeni ...... matic review and meta-analysis
@en
P2093
Benkang Shi
Dongqing Zhang
Xinyue Liang
Yaofeng Zhu
P2860
P304
P356
10.1111/JCH.12273
P407
P577
2014-03-01T00:00:00Z